Back to results
US 2013/0171662 A1Published application
Assay
AssigneeCytosystems Limited
InventorRonald Alfred Laskey
Life of this patent
Estimating the term…
Abstract
This disclosure relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.
Claims26
A diagnostic or prognostic assay for the detection of prostate cancer cells in a biological sample comprising the steps:
- i) obtaining an isolated cell sample from said biological sample and contacting the isolated cell sample with a binding agent that specifically binds at least one MCM polypeptide;
- ii) contacting the isolated cell sample with a further binding agent that specifically binds an androgen receptor polypeptide [AR];
- optionally iii) contacting the isolated cell sample with a still further binding agent that specifically binds prostate specific antigen [PSA];
- iv) detecting the binding of two or more binding agents;
- and
- v) determining the number of cells in said isolated cell sample that positively bind two or more binding agents, wherein the number of positive cells is an indicator of the presence of prostate cancer cells in the biological sample.
3 more elements
A diagnostic or prognostic assay for the determination of prostate cancer in a subject comprising the steps:
- i) obtaining a first isolated biological sample and contacting the sample with a binding agent that specifically binds PSA;
- optionally
- ii) detecting the presence of PSA in said sample;
- iii) obtaining a second biological sample from the subject, preparing an isolated cell sample and contacting said cell sample with first and second binding agents that specifically bind at least one MCM polypeptide and an androgen receptor polypeptide;
- iv) detecting the presence of said MCM polypeptide[s] and androgen receptor;
- and
- v) determining the number of cells in said isolated cell sample that positively bind both MCM and androgen receptor, wherein the number of positive cells is an indicator of the presence of prostate cancer cells.
4 more elements
A kit comprising first, second and third binding agents wherein said agents bind a MCM polypeptide, androgen receptor polypeptide and prostate specific antigen polypeptides respectively,
Dependencies are inferred from the claim text.